Evidence supporting the use of: Citicoline
For the health condition: Addictions (drugs)
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Citicoline (CDP-choline) has been investigated for its potential role in supporting the treatment of substance use disorders, including cocaine and other drug addictions. The rationale is based on citicoline's modulation of brain phospholipid metabolism, neuroprotective effects, and its influence on neurotransmitter systems, particularly dopamine and acetylcholine. These neurotransmitters are involved in the brain's reward pathways, which are dysregulated in addiction.
Some clinical studies have explored citicoline's efficacy in reducing drug cravings and improving cognitive deficits associated with addiction. For example, a few small randomized controlled trials (RCTs) have shown that citicoline may decrease cocaine use and craving, as well as improve attention and executive function in individuals with substance use disorders. However, these studies are generally limited by small sample sizes and short durations. A 2014 review concluded that while citicoline shows promise, the evidence is preliminary and not yet robust enough to support routine clinical use for addiction treatment.
In summary, there is some scientific basis and early clinical research supporting the use of citicoline as an adjunct in the treatment of addiction, particularly stimulant use disorders, but the overall evidence is of low to moderate quality (rated 2 out of 5). Larger and more rigorous studies are needed to confirm its efficacy and define its role in addiction therapy.
